Epidermal growth factor receptor (EGFR) is the most common driver mutation in NSCLC, specifically adenocarcinomas (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). This evidence concerns the gene EGFR and adenocarcinoma.